Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03356808 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Antigen-specific T Cells Against Lung Cancer

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Jun 1, 2027
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v7
  2. Primary completion date: Jan 1, 2020 to Dec 31, 2029
    • Start date: Dec 15, 2017 to Jun 1, 2026
    • Study sites: 3 to 1
    • Study completion date: Dec 31, 2020 to Dec 31, 2030
    v6
  3. Re-verified, no change to tracked fieldsv5
  4. Site contacts updated at 1 of 3 sitesv4
  5. Primary completion date: Jan 1, 2019 to Jan 1, 2020v3 Show 7 more changesShow less
    • Primary endpoint revised
    • Study sites: 1 to 3
    • Interventions: Lung cancer-specific CAR-T cells (Biological) to Lung cancer-specific T cells (Biological)
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints revised (2)
    • Study description expanded, about 41 words
    • Study title revised
  6. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.
Trial Details
NCT Number NCT03356808
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Lung Cancer
Related terms Lung Neoplasms, Medullary cystic kidney disease 1
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov